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The homeodomain protein TGIF (TG-interacting
factor) restricts TGF-b/Smad cytostatic signaling by
interfering with the nucleocytoplasmic transit of the
tumor suppressor cPML. Here, we identify PHRF1
as a ubiquitin ligase that enforces TGIF decay by
driving its ubiquitination at lysine 130. In so doing,
PHRF1 ensures redistribution of cPML into the cyto-
plasm, where it associates with SARA and coordi-
nates activation of Smad2 by the TGF-b receptor.
The PHRF1 gene resides within the tumor suppres-
sor locus 11p15.5, which displays frequent loss in a
wide variety of malignancies, including breast can-
cer. Remarkably, we found that the PHRF1 gene is
deleted or silenced in a high proportion of human
breast cancer samples and cancer cell lines. Recon-
stitution of PHRF1 into deficient cells impeded their
propensity to form tumors in vivo, most likely
because of the reemergence of TGF-b responsive-
ness. These findings unveil a paradigm behind inac-
tivation of the cPML tumor suppressor network in
human malignancies.
INTRODUCTION
TGIF (TG-interacting factor) belongs to the superfamily of home-
odomain proteins that regulate a vast array of biological pro-
cesses, including embryonic development, proliferation, and
differentiation. TGIF was originally identified by virtue of its ability
to compete with retinoid receptors for binding to their cognate
promoters and thereby suppresses retinoic acid (RA) signaling
(Bertolino et al., 1995). Besides retinoic signaling, TGIF was530 Cell Reports 4, 530–541, August 15, 2013 ª2013 The Authorsshown to function as a suppressor of TGF-b (transforming
growth factor b) signaling, which regulates cell fate in a variety
of physiological contexts ranging from embryonic development
to adult tissue homeostasis (Feng and Derynck, 2005; Whitman,
1998). TGF-b initiates responses by contacting two types of
transmembrane Ser/Thr kinases called type I (TbRI) and type II
(TbRII) receptors, promoting phosphorylation and activation of
TbRI by the TbRII kinase (Massague´ et al., 2005). In the canonical
pathway, the activated TbRI propagates signals by phosphory-
lating Smad2 and Smad3 (Smad2/Smad3), a process coordi-
nated by the adaptor protein SARA (Smad anchor for receptor
activation) (Tsukazaki et al., 1998). The phosphorylation of
Smad2/Smad3 also depends on their interaction with the cyto-
plasmic variant of the promyelocytic leukemia protein (cPML),
whose functions are first to bridge together Smad2/Smad3 and
SARA and then to bring that complex within the proximity of
the TGF-b receptor (Lin et al., 2004; Seo et al., 2006). Phosphor-
ylation of Smad2/Smad3 induces dissociation from SARA and
cPML with concomitant association with Smad4 and transloca-
tion to the nucleus, where they induce expression of TGF-b
target genes through cooperative interaction with general coac-
tivators, prominent among them p300/CBP (Massague´ et al.,
2005).
Although TGIF was initially thought to function in the nucleus
as a Smad transcriptional corepressor because of its ability to
associate with histone deacetylases (HDACs), recent advances
made in our laboratory argue that the TGIF inhibitory action
mainly proceeds via mechanisms unrelated to transcriptional
repression. For instance, we have demonstrated that TGIF can
facilitate degradation of active Smad2/Smad3 through recruit-
ment of the E3 ubiquitin ligase WWP1/Tiul1, although this func-
tion appears to be restricted to terminating TGF-b signaling
(Seo et al., 2004). Moreover, we found that TGIF can function
at early steps to constrain initiation of Smad signaling, presum-
ably by shifting the nucleocytoplasmic shuttling of cPML toward
the nucleus, in turn precluding the assembly of cPML-SARA
complex that is instrumental to Smad2/Smad3 phosphorylation
by TbRI (Faresse et al., 2008; Lin et al., 2004; Seo et al., 2006).
The PML gene encodes a tumor suppressor that was initially
identified in patients with acute promyelocytic leukemia (APL),
where it is fused to RARa as a consequence of reciprocal
t(15;17) chromosomal translocations (Salomoni and Pandolfi,
2002; Scaglioni and Pandolfi, 2007). In transgenic mice, expres-
sion of PML-RARa in the myeloid lineage causes leukemia with
features of APL. Functionally, PML controls a variety of pro-
cesses, such as growth suppression, apoptosis, or senescence
(Salomoni and Pandolfi, 2002; Scaglioni and Pandolfi, 2007). The
ability of PML to achieve such tumor suppressor responses un-
derscores the possibility that its recurrent inactivation may also
culminate in the pathogenesis of nonhematological malig-
nancies. Unequivocal support to this concept came with the
demonstration that PML-deficient mice are more susceptible
to chemical- or oncogene-induced carcinogenesis in multiple
tissues (Salomoni and Pandolfi, 2002; Scaglioni and Pandolfi,
2007). From a clinical point of view, PML inactivation has been
noted in a large portion of human cancers, where it correlates
with poor prognosis (Gurrieri et al., 2004). Notwithstanding these
intriguing hints highlighting the vulnerability of PML to alterations
that are inherent to cancer development, at this point, it is
becoming increasingly obvious that additional efforts should
be put into the discovery of mechanistic paradigms of PML inac-
tivation, given that they remain, for the most part, elusive. The
present study sheds light on these persistent concerns because
we identify and characterize PHRF1 as a TGIF ubiquitin ligase
whose deficiency culminates in impairment of the cPML tumor
suppressor network that empowers TGF-b-induced cytostatic
responses. We provide proof-of-principle experiments that the
PHRF1 gene is somatically altered in a high proportion of breast
cancers, findings that could have a profound impact on our abil-
ity to predict breast cancer rates in large numbers of patients and
may even influence screening, follow-up, and treatment options.
RESULTS
Interaction of PHRF1 with TGIF
To identify potential modifiers of the TGIF/cPML interplay that
could be prone to disruption in cancer, we undertook a yeast
two-hybrid approach using TGIF as bait. Screening of a human
universal cDNA library yielded recovery of a gene with unknown
functions, named in databases as PHRF1 (PHD and RING
finger 1). PHRF1 possesses an N-terminal PHD/bromodomain
followed by a RING finger and a large C-terminal domain of
unique sequence (see Figure 2G). To determine whether
PHRF1 binds to TGIF in mammalian cells, we conducted coim-
munoprecipitation experiments using transfected MDCK cells.
As shown in Figure 1A, PHRF1 interacts robustly with TGIF at
steady state, and exposure of cells to TGF-b induced a marked
decrease in this interaction, which became apparent only at 2 hr
poststimulation and persisted for at least 6 hr. This decrease
depends on protein neosynthesis because cotreatment of
cells with the transcription inhibitor actinomycin D blocked
TGF-b-induced disassembly of the PHRF1-TGIF complex (Fig-
ure S1C). The interaction of PHRF1with TGIF is specific becausePHRF1 failed to interact with c-Ski (Figure 1B), which shares with
TGIF many biological properties related to suppression of TGF-b
signaling (Massague´ et al., 2005). Likewise, we were unable to
detect an interaction between TGIF and Ectodermin (Figure 1C),
another PHD/RING finger-containing protein operating in the
TGF-b signaling pathway (Dupont et al., 2009).
To analyze in more detail the PHRF1-TGIF interaction, we
sought to define the domains that mediate their interaction.
Employing various TGIF deletion mutants, we mapped the
PHRF1-interacting region to the middle region of TGIF between
amino acids 148 and 164 (Figures 1D and S1A). Reciprocally, we
tested the interaction of a series of PHRF1 deletion mutants with
TGIF and found that TGIF bound to the N-terminal domain span-
ning the PHD/RING finger motif (Figure 1E).
Next, we raised a highly specific antibody for PHRF1, as
gauged by immunoblotting of extracts from cells either overex-
pressing or depleted of PHRF1 by small hairpin RNA (shRNA)
(Figure S1B). Using two TGF-b-sensitive cell lines, HepG2 and
HaCat, we could clearly detect a strong interaction between
endogenous PHRF1 and TGIF, but this was decreased in
response to TGF-b, becoming manifest 2–4 hr poststimulation
(Figure 1F). Together, these results demonstrate that PHRF1
and TGIF can form a physical complex whose stoichiometry ap-
pears to decline upon prolonged activation of TGF-b signaling.
PHRF1 Contributes to TGF-b Signaling
We next wondered whether expression of PHRF1 could influ-
ence critical aspects of TGF-b signaling, such as transcriptional
and cytostatic responses. Notably, overexpression of PHRF1
enhanced the ability of TGF-b to induce transcription from two
distinct reporters, CAGA9-Lux and ARE3-Lux, which are read-
outs of Smad3 and Smad2, respectively (Figure S2A). This
finding was further substantiated by using MDCK cells stably
overexpressing PHRF1, which showed that ectopic expression
of PHRF1 was effective in enhancing the sensitivity of cells to
TGF-b-induced expression of endogenous PAI-1 and growth
arrest (Figures 2A and 2B). Such ability of PHRF1 to foster
TGF-b signaling likely represents a widespread phenomenon
because HepG2 or HaCat cells stably overexpressing PHRF1
also displayed enhanced sensitivity to TGF-b-induced expres-
sion of PAI-1 as well as growth arrest (Figures S2B and S2C).
Of note, TGF-b stimulation did not induce apoptosis or senes-
cence in these cells (data not shown), suggesting that PHRF1
may contribute to the ability of TGF-b to block DNA synthesis
and progression through the cell cycle.
We also investigated whether PHRF1 deficiency could affect
TGF-b transcriptional and growth inhibitory responses. In tran-
sient transfection experiments, expression of two independent
specific siRNAs both induced a marked decrease in TGF-
b-induced CAGA9-Lux activity (Figure S2D). To further demon-
strate that depletion of PHRF1 disrupts TGF-b signaling while
further ruling out off-target effects, we initially generated
MDCK cells stably expressing a shRNA targeting a third region
of PHRF1 (sh-PHRF1). As anticipated, depletion of PHRF1 in
MDCK cells prevented TGF-b-induced expression of endoge-
nous PAI-1 and growth arrest (Figures 2C and 2D). We also
generated HepG2 or HaCat cells stably expressing two indepen-
dent PHRF1 shRNAs and again found that PHRF1 knockdownCell Reports 4, 530–541, August 15, 2013 ª2013 The Authors 531
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Figure 1. PHRF1 Interacts with TGIF
(A) MDCK cells were transfected with Flag-PHRF1 in the absence or presence of HA-TGIF and treated with TGF-b for increasing times. Cell lysates were
subjected to anti-HA immunoprecipitation (IP) followed by immunoblotting (IB) with anti-Flag. In this and all the following experiments, the expression of proteins
under investigation (input) was determined by direct immunoblotting.
(B and C) 293 cells were transfected with the indicated combinations of HA-TGIF, Flag-PHRF1, HA-c-Ski, and Flag-Ecto. Cell lysates were subjected to anti-HA
(B) or anti-Flag (C) immunoprecipitation followed by immunoblotting with anti-Flag (B) or anti-HA (C).
(D and E) Mapping the regions of TGIF and PHRF1 that mediate their interaction using extracts from 293 cells transfected with the indicated combinations of TGIF
and PHRF1 deletion mutants is shown. WT, wild-type.
(F) HepG2 or HaCat cells were left untreated or treated with TGF-b for increasing times, and extracts were immunoprecipitated with anti-TGIF or IgG. Immune
complexes were detected by immunoblotting with anti-PHRF1.
See also Figure S1.was able to block TGF-b-induced expression of PAI-1 as well as
expression of two other endogenous TGF-b/Smad target genes,
Smad7 and JunB (Figures 2E and S2E). Depletion of PHRF1 in
HaCat or HepG2 cells also blunted the growth inhibitory effect
of TGF-b (Figure 2F), in line with the idea that PHRF1 functions
as a bona fide component of the TGF-b signaling pathway inmul-
tiple cell systems. In another strategy, taking advantage of our
discovery of cancer cell lines deficient in PHRF1 (e.g., MCF7-
TR and MDA-MB435), we found that restoration of PHRF1
expression rendered cells responsive to TGF-b-induced expres-
sion of PAI-1 and growth arrest (see Figures 6F, 6G, S6F, and
S6G). Collectively, these results argue that PHRF1 is a critical
determinant of TGF-b responses, and they further raise the inter-532 Cell Reports 4, 530–541, August 15, 2013 ª2013 The Authorsesting possibility that loss of PHRF1 may attenuate TGF-b cyto-
static signaling in cancer cells.
To gain initial insights into the mode of action of PHRF1, we
attempted to rescue the TGF-b transcriptional response in
MCF7-TR using our panel of PHRF1 deletion mutants. Interest-
ingly, expression of either PHRF1.mutA or PHRF1.mutC, which
includes the RING finger and retains their TGIF binding proper-
ties, rescued TGF-b transcriptional responses (Figures 1E and
2G). However, none of the other two mutants (i.e., mutB and
mutD) that we tested restored TGF-b responsiveness. Because
none of the later mutants binds to TGIF, we concluded that the
physical interaction between PHRF1 and TGIF is essential for
the ability of PHRF1 to promote TGF-b signaling.
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Figure 2. PHRF1 Promotes TGF-b Signaling
(A and B) MDCK cells stably expressing empty
vector or PHRF1 were treated with 200 pM TGF-b
for increasing times. (A) Cell lysates were analyzed
by immunoblotting using antibodies against PAI-1,
Flag, or Smad4 as a loading control. (B) Cells were
counted automatically using a cell counter, and
the results (mean ± SD of triplicates) were ex-
pressed as the percentage of cells cultured in the
absence of TGF-b.
(C andD)MDCKcells stably expressing scrambled
or sh-PHRF1 were treated with 200 pM TGF-b for
increasing times. Then, TGF-b-induced expres-
sion of PAI-1 (C) or growth arrest (D) was deter-
mined as described in (A) and (B), respectively.
(E and F) HaCat or HepG2 cells were stably
transfected with scrambled or two different
shRNAs (sh1-PHRF1 and sh2-PHRF1) and treated
with or without TGF-b for 16 hr (E) or 24 hr (F). (E)
Expression of PAI-1 was determined by immu-
noblotting. (F) Cell proliferation was determined
by the incorporation of BrdU, and the results
(absorbance at 450 nm) were expressed as
mean ± SD of triplicates from a representative
experiment performed three times.
(G) MCF7-TR cells were transfected with CAGA9-
Lux and PHRF1 deletion mutants, treated with or
without TGF-b, and analyzed for luciferase activ-
ity. Data are expressed as mean ± SD (n = 3).
See also Figure S2.PHRF1 Induces TGIF Degradation
Quite unexpectedly, we noticed during our earlier analyses of the
PHRF1/TGIF interaction that overexpression of PHRF1 resulted
in decreased expression of the TGIF protein in a manner depen-
dent on their association (Figure 1D). We also noticed that acti-
vation of TGF-b signaling induced accumulation of the TGIF
protein, concurring with decreased association of PHRF1 and
TGIF (Figures 1A and 1F). Crucially, under the same experimental
conditions, TGF-b did not affect the abundance of TGIF mRNA
(Figure S3A). Together, these findings provide initial hints that
PHRF1 might affect TGIF stability. We at first attempted to
corroborate this notion by demonstrating that, although deple-
tion of PHRF1 dramatically increased the abundance of theCell Reports 4, 530–541endogenous TGIF protein, it failed to
affect the abundance of TGIF mRNA (Fig-
ures 3A and S3B). Next, we reasoned that
if PHRF1 indeed compromises TGIF sta-
bility, then expression of PHRF1 should
modulate biological processes other
than TGF-b signaling that are subject to
regulation by TGIF, such as repression
of RA signaling. In fact, overexpression
of PHRF1 enhanced RA-induced tran-
scription with efficiency similar to that
elicited by depletion of TGIF (Figure S3C).
As a specificity control, expression of
PHRF1 did not influence the activity of a
Notch reporter, similar to depletion of
TGIF (Figure S3D). Hence, PHRF1 andTGIF appear to regulate the same cellular functions but with
opposite outcomes, which is in consonance with the hypothesis
that PHRF1 may hamper TGIF stability.
Having discovered that PHRF1 affects the abundance of the
TGIF protein, we next investigated the possibility that PHRF1
might function as a TGIF ubiquitin ligase. As shown in Figure 3B,
treatment of cells with the proteasome inhibitor MG132 pre-
vented PHRF1-induced TGIF degradation. In alternative experi-
mental approaches, we found that overexpression of PHRF1 not
only provoked a striking increase in ubiquitin-conjugated TGIF
protein but also enhanced its turnover (Figures 3C and 3D). To
directly demonstrate that PHRF1 functions as a TGIF ubiquitin
ligase, we introduced a point mutation in the RING finger, August 15, 2013 ª2013 The Authors 533
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Figure 3. PHRF1 Triggers TGIF Degradation
(A) Lysates of MDCK cells stably transfected with
scrambled or two different PHRF1 shRNAs (sh1-
PHRF1 and sh2-PHRF2) were analyzed by immu-
noblotting using antibodies against PHRF1, TGIF,
or Smad4 as a loading control.
(B–E) 293 cells were transfected with the indicated
combination of HA-TGIF, Flag-PHRF1, Flag-
PHRF1.CA, and His-Ub. (B) Cells were treatedwith
vehicle or MG132 for 6 hr and analyzed by
immunoblotting. (C) Cells were incubated with
MG132 for 6 hr, and lysates were pulled down
(PD) with nickel-Sepharose and immunoblotted
with anti-HA. To detect the interaction of TGIF with
PHRF1, extracts were immunoprecipitated with
anti-Flag and immunoblotted with anti-HA.
(D) Cells were incubated with cycloheximide (CHX)
for various time periods before being analyzed
by immunoblotting. The expression levels of
TGIF were determined by scanning laser densi-
tometry, and the results were expressed as the
percentage of control at time 0. The half-life of
TGIF is indicated.
(E) Expression of TGIF or PHRF1 was determined
by immunoblotting.
(F) In vitro ubiquitination assay was performed
using purified His6-TGIF, GST-PHRF1, or GST-
PHRF1.CA, and recombinant ubiquitin, E1, and
UbcH5a. To detect ubiquitinated TGIF, samples
were subject to immunoblotting with anti-His.
To detect the association of TGIF with PHRF1,
samples were pulled down with glutathione-
Sepharose and immunoblotted with anti-His.
See also Figure S3.(Cys108Ala), creating an inactivemutant (PHRF1.CA) that retains
normal TGIF binding capability. In contrast to wild-type PHRF1,
PHRF1.CA behaved as a dominant-negative mutant to boost the
steady-state level of TGIF while decreasing its polyubiquitination
(Figures 3C and 3E). An in vitro ubiquitination assay using puri-
fied proteins confirmed that PHRF1 was effective in catalyzing
TGIF polyubiquitination, whereas PHRF1.CA was void of any
enzymatic activity (Figure 3F).
PHRF1 Promotes TGF-b Signaling by Inducing
Ubiquitination of TGIF at Lysine 130
To investigate in more detail the mechanism by which PHRF1
promotes TGIF degradation, we individually substituted all of
the Lys by Arg (except Lys2, Lys4, Lys5, Lys100, and Lys103
that were processed simultaneously, given their close proximity
in TGIF) and tested for their destabilization by PHRF1. The result
indicated that only mutation of Lys130 (TGIF.K130R), which lies
close to the PHRF1-interacting motif, made TGIF resistant to
PHRF1 (Figure 4A). To corroborate this result, we designed
several experiments to compare the ubiquitin-dependent degra-
dation of TGIF.K130R and wild-type TGIF. Initially, we employed
a FlpIn-dependent recombination system to achieve a single
copy integration of TGIF mutants at the same genomic locus
under the control of a Dox-inducible promoter, thereby avoiding
any fluctuations that could arise from transient transfection or
integration of multiple copies. As expected, these isogenic cell
lines expressed similar levels of TGIF and TGIF.K130R mRNAs
following induction with Dox (Figure S4A). However, immuno-534 Cell Reports 4, 530–541, August 15, 2013 ª2013 The Authorsblotting revealed higher expression of TGIF.K130R, a difference
that was abolished by MG132, which is indicative of increased
stability of TGIF.K130R (Figure S4B). Next, we used the FlpIn
cell system to compare the decay rate of TGIF and TGIF.K130R
following Dox relaxation and found that TGIF.K130R dis-
played decreased turnover (Figure 4B). Finally, we found that
TGIF.K130R was less polyubiquitinated than TGIF (Figure 4C).
Of note, we used TGIF.K159R as an alternative control and found
its ubiquitination status to be similar to that of wild-type TGIF
(Figure 4C). These results indicate that a physiological function
of PHRF1 is to trigger TGIF polyubiquitination at Lys130, with
subsequent clearance through the proteasome pathway.
These preceding data at least suggest that targeting TGIF for
degradation may be one of the possible mechanisms by which
PHRF1 promotes TGF-b signaling. Consistent with this view,
enforced expression of PHRF1.CA exerted a dominant-negative
effect on TGF-b transcriptional responses, yet this was blunted
by TGIF depletion (Figure 4D). To exclude the possibility that
PHRF1 might deploy other mechanisms to foster TGF-b sig-
naling, we sought to determine the extent to which enforced
expression of PHRF1 affects the ability of TGIF.K.130R versus
wild-type TGIF to suppress TGF-b-induced transcription, with
the assumption that TGIF.K130R would preserve its inhibitory
activity owing to escape from degradation by PHRF1. In contrast
to wild-type TGIF, the inhibitory effect of TGIF.K130R was insen-
sitive to coexpression of PHRF1 (Figure 4D). In a control sample,
expression of PHRF1.CA was ineffective in relieving the inhibi-
tory effect of TGIF (Figure 4D), lending further support to the
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Figure 4. PHRF1PromotesUbiquitination of
TGIF at Lys 130
(A) Effects of Flag-PHRF1 on the abundance of
HA-TGIF Lys mutants were determined by immu-
noblotting analysis of lysates from transfected 293
cells.
(B) 293 FlpIn cells stably expressing wild-type
HA-TGIF or HA-TGIF.K130Rwere treatedwith Dox
for 24 hr. Then, cells were incubated in regular
media for increasing times and subjected to
immunoblotting. The half-life of each TGIF mutant
is indicated.
(C) 293 cells were transfected with His-Ub
together with HA-TGIF, HA-TGIF.K130R, or
HA-TGIF.K159R, and cells were treated with
MG132 for 6 hr. Then, cell lysates were pulled
down with nickel-Sepharose and immunoblotted
with anti-HA.
(D) HepG2 cells were transfected with CAGA9-
Lux and the indicated combinations of TGIF,
TGIF.K130R, PHRF1, PHRF1.CA, and sh-TGIF,
treated with or without TGF-b, and processed for
luciferase activity. Data are expressed as mean ±
SD (n = 3).
See also Figure S4.hypothesis that the biological activity of PHRF1 in TGF-b
signaling stems primarily from its ubiquitin ligase activity toward
TGIF, rather than other mechanisms.
PHRF1 Facilitates cPML Function in TGF-b Signaling
The possibility raised by the foregoing observation, that PHRF1
promotes TGF-b signaling by opposing TGIF, was further inves-
tigated by evaluating another process affected by TGIF, namely
phosphorylation of Smad2 (Faresse et al., 2008; Seo et al., 2006).
As anticipated, TGF-b stimulation induced a transient increase in
Smad2 phosphorylation, which peaked at 1 hr and gradually
declined in the presence of continuous TGF-b, inversely corre-
lating with changes in TGIF abundance (Figure S1D). Remark-
ably, depletion of PHRF1 in MDCK cells blocked TGF-b-induced
phosphorylation of endogenous Smad2, a phenomenon that can
be further supported by the impaired assembly of the endoge-
nous Smad2/Smad4 complex, the formation of which depends
on Smad2 phosphorylation (Figures 5A and 5B). On the other
hand, we detected a marked increase in the sensitivity of cells
to TGF-b-mediated phosphorylation of endogenous Smad2 in
MDCK, HepG2, or HaCat cells stably overexpressing PHRF1
(Figures S5A and S5B).
Next, we carried out experiments to examine whether PHRF1
facilitates Smad2 phosphorylation by a mechanism that is
dependent on TGIF. As shown in Figure S5C, overexpression
of PHRF1 was able to counteract TGIF-suppressed Smad2
phosphorylation. In an alternative strategy, depletion of PHRF1
in control cells blocked Smad2 phosphorylation, whereas deple-
tion of PHRF1 in cells that were simultaneously depleted of
TGIF had little or no effect on Smad2 phosphorylation (Fig-
ure 5C), strengthening the hypothesis that PHRF1 may promoteSmad2 phosphorylation by a mechanism that relies upon TGIF
degradation.
One major mechanism by which TGIF suppresses Smad2
phosphorylation depends on its ability to sequester cPML in
the nucleus (Faresse et al., 2008; Seo et al., 2006). Owing
to its capability to destabilize TGIF, PHRF1 could promote
Smad2 phosphorylation by facilitating relocalization of cPML
into the cytoplasm. In an initial effort to approach this question,
we found that depleting PHRF1 in MDCK cells prevented as-
sembly of the endogenous cPML/SARA complex (Figure 5D),
which is known to occur in the cytoplasm in the absence of
TGF-b signaling (Faresse et al., 2008; Lin et al., 2004).
Conversely, stable expression of PHRF1 in MDCK cells resulted
in a marked increase in the association of endogenous cPML
and SARA (Figure 5E). To extend these results, we carried
out immunofluorescence experiments to determine whether
depletion of PHRF1 could affect the subcellular distribution of
endogenous cPML. Analysis of control cells showed that some
of the PML staining localized to distinctive nuclear bodies,
although strong diffuse cytoplasmic staining, which is reminis-
cent of cPML distribution, could also be detected (Figure 5F),
as previously reported by Faresse et al. (2008), Lin et al.
(2004), and Seo et al. (2006). Interestingly, depletion of PHRF1
resulted in the disappearance of the immunofluorescence stain-
ing in the cytoplasm, which likely occurred as a consequence of
increased accumulation of the total TGIF pool in the nucleus
(Figure S5D). A similar result was obtained by means of a cell
fraction approach (Figure S5E). Thus, by fostering TGIF clear-
ance, PHRF1 promotes cPML movement into the cytoplasm,
where it functions in conjunction with SARA to facilitate
Smad2 phosphorylation.Cell Reports 4, 530–541, August 15, 2013 ª2013 The Authors 535
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Figure 5. PHRF1 Facilitates cPML Function in TGF-b Signaling
(A and B) MDCK-scrambled, MDCK-sh1-PHRF1, or MDCK-sh2-PHRF1 cells were treated with or without TGF-b for increasing times (A) or 1 hr (B). (A) The
phosphorylation of Smad2 was assessed by immunoblotting with anti-pSmad2. (B) The association of Smad2 with Smad4 was analyzed by blotting anti-Smad4
immunoprecipitates with anti-Smad2.
(C) 293 cells were transfected with the indicated combinations of scrambled, siTGIF, and siPHRF1, and cultured with or without TGF-b for 1 hr. Then, the
phosphorylation of Smad2 was assessed by immunoblotting.
(D and E) MDCK cells stably depleted for (D) or overexpressing (E) PHRF1 were treated with or without TGF-b for 1 hr, and the association of endogenous cPML
with SARA was visualized by blotting anti-SARA immunoprecipitates with anti-PML.
(F) MDCK-scrambled, MDCK-shPHRF1, or MDCK-shPHRF2 cells were immunostained with anti-PML (red) or DAPI (blue).
(legend continued on next page)
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To directly demonstrate that PHRF1 promotes Smad2
phosphorylation by facilitating relocalization of cPML into the
cytoplasm, we conducted comparative experiments using
wild-type and PML/ MEFs. We surmised that PML deficiency
would compromise PHRF1-induced Smad2 phosphorylation if
this merely proceeds through the release of cPML from nuclear
retention constraint due to TGIF destabilization. In fact, overex-
pression of PHRF1 enhanced TGF-b-induced phosphorylation
of Smad2 in wild-type MEFs but failed to do so in PML/
MEFs (Figure 5G), indicating that PHRF1 and cPML function in
the same biochemical circuit that governs Smad2 phosphoryla-
tion. In a control sample, add back of cPML into PML/ MEFs
restored TGF-b-induced Smad2 phosphorylation to the level
detected in wild-type MEFs.
The data described so far suggest that cPML is epistatic to
PHRF1 and strengthen the notion that PHRF1 might function to
facilitate relocalization of cPML to the cytoplasm, where it coor-
dinates phosphorylation of Smad2. If this prediction holds true,
then cPML deficiency should impinge on PHRF’s ability to pro-
mote TGF-b signaling. To probe this possibility, we chose to
deplete cPML in HaCat or HepG2 cell lines we engineered to
express PHRF1 under the control of a Dox-inducible promoter.
As expected, induction of PHRF1 expression enhanced TGF-
b-induced growth arrest and expression of PAI-1, Smad7, and
JunB. Crucially, depletion of cPML severely blunted those
effects (Figures 5H, 5I, and S5F). To validate this finding, we
devised a reciprocal strategy aimed at investigating whether
PHRF1 deficiency could impinge on cPML’s ability to promote
TGF-b signaling. As expected, stable reconstitution of PML/
MEFs with cPML rescued the sensitivity of cells to TGF-
b-induced growth arrest and expression of PAI-1, Smad7, and
JunB (Figures S5G and S5H). Remarkably, depletion of PHRF1
rendered cPML-reconstituted PML/ MEFs again resistant to
TGF-b, further underscoring the epistatic relationship between
PHRF1 and cPML.
Deregulated Expression of PHRF1 in Human Breast
Cancer
Interrogation of databases revealed that the PHRF1 gene maps
to 11p15.5, a strong candidate tumor suppressor locus display-
ing frequent loss of heterozygosity (LOH) in several human solid
cancers, including breast cancer (Ali et al., 1987; Jonas and
Kimonis, 2001; Karnik et al., 1998; Winqvist et al., 1995). It is
also worth mentioning that two recent independent studies
reported two somatic mutations in the PHRF1 gene in breast
cancer: one of them is a missense mutation, whereas the other
is located within an intron (Ellis et al., 2012; Nik-Zainal et al.,
2012). Moreover, we found a deletion and several point muta-
tions in the PHRF1-coding region in other types of cancer
(http://www.sanger.ac.uk), further suggesting that PHRF1 may(G) PML+/+ or PML/MEFs were transfected with the indicated combinations of M
1 hr. The phosphorylation of Smad2 was visualized by blotting anti-Myc immuno
(H and I) HepG2 or HaCat cells stably expressing Dox-inducible PHRF1 were inf
PML (sh1-PML and sh2-PML). Cells were left untreated or treated with Dox for 24
proliferation was determined by the BrdU method, and data are expressed as m
PAI-1, Flag, PML, or Smad4 as a loading control.
See also Figure S5.display the prominent hallmarks of a tumor suppressor gene.
These facts, together with our preceding findings revealing
PHRF1 as a key player in the TGF-b cytostatic program, promp-
ted us to assess the clinical relevance of PHRF1 in human can-
cers. Accordingly, we performed qRT-PCR experiments using
106 breast tumor samples representing a progressive spectrum
of neoplasia, ranging from benign breast tumors to advanced
metastasis. When compared with adjacent normal tissue, a
marked decrease in PHRF1 mRNA (cutoff value of more than a
2-fold decrease) was detected, even at early stages of neoplasia,
although the frequency of such alteration tends to increase in
more advanced stages, reaching 57% of samples from patients
with metastasis (Figures 6A and 6B). We cross-validated this
finding by gene expression profiles (up to 28%decrease) derived
from two data sets summarizing 786 breast cancers: E-MTAB-
365 and GSE4922 (Guedj et al., 2012; Ivshina et al., 2006).
During the course of these analyses, we also found a robust cor-
relation (correlation coefficient, 0.74; p < 0.001) between expres-
sion of PHRF1 and probable activation of TGF-b signaling, using
combined expression of p21, p15, PAI-1, and JunB as a TGF-b
signature.
Next, we extended our analysis to genomic DNA, seeking
possible alterations in the PHRF1 gene. To this end, we used
high-resolution array CGH to quantify DNA copy number of the
PHRF1 gene in a series of 37 primary breast tumors. The result
indicated that eight samples (21.6%) carried deletion of the
PHRF1 gene (Figures S6A and S6B). This deletion appears to
be specific because many neighboring genes were not affected
or even amplified. Consistent with our findings, recent ana-
lyses (http://www.broadinstitute.org/tcga/home) indicated that
PHRF1 is significantly deleted across the entire data set of the
4,404 tumors analyzed at the Broad Institute, including breast
cancer (20.9%) (Figures S6A and S6C). Comparative analysis
indicated that deletion of PHRF1 occurs with a frequency
approaching that of BRCA1 (31%) or BRCA2 (26%), the most
prominent tumor suppressor genes of breast cancer. Together,
these observations strongly suggest that PHRF1 is frequently
deleted or mutated in breast cancer and that somatic alterations
in the PHRF1 gene might account, at least in part, for the loss of
PHRF1 mRNA expression.
To begin dissecting the impact of PHRF1 loss on breast
cancer pathogenesis, we screened a number of human breast
cancer cell lines for PHRF1 deficiency. Analysis of PHRF1
mRNA revealed that two out of eight (25%) of the cell lines dis-
played a near-complete extinction of PHRF1 expression (Figures
6C and 6D), which is in excellent agreement with the frequency of
PHRF1 loss in tumor samples. Here again, we cross-validated
the loss of PHRF1 in breast cancer cell lines by researching pub-
lic databases (http://www.sanger.ac.uk). Our efforts revealed
that 19 out of 53 (30%) exhibit LOH at the PHRF1 locus.yc-Smad2, HA-PHRF1, and Flag-cPML, and treated with or without TGF-b for
precipitates with anti-pSmad2.
ected with lentiviruses encoding scrambled or two different shRNAs targeting
hr before being treated with or without TGF-b for 24 hr (H) or 16 hr (I). (H) Cell
ean ± SD (n = 3). (I) Cell lysates were immunoblotted with antibodies against
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Figure 6. Deregulation of PHRF1 in Breast
Cancer
(A and B) Expression of PHRF1 mRNA in human
breast cancer samples was determined by qRT-
PCR, and the results were normalized on the
basis of TBP expression. (A) The results are
represented as the median of normalized ex-
pression of PHRF1 mRNA in each sample during
different stages of tumor progression (*p < 0.05,
**p < 0.01). (B) Percentage of samples with low
expression of PHRF1 mRNA in each stage of
tumor progression (cutoff value of more than
2-fold decrease) is shown.
(C and D) Expression of PHRF1 mRNA in human
cancer cell lines was determined by qRT-PCR,
and the results were normalized on the basis of
TBP expression and expressed as mean ± SD
(n = 3) (C). Portions of the qRT-PCR products
were analyzed by agarose gel (D).
(E and F) MCF7-TR cells stably transfected with
empty vector or PHRF1 were treated with or
without TGF-b for 1 hr (E) or 16 hr (F). Then, the
association of endogenous cPML and SARA (E),
phosphorylation of Smad2 (E), or expression of
PAI-1 (F) was examined.
(G) MCF7-TR cells stably transfected with empty
vector or PHRF1 were treated with increasing
doses of TGF-b for 24 hr, and cell proliferation
was determined by the thymidine incorporation
method. Data (mean ± SD of triplicates) are ex-
pressed as percentage of the radioactivity incor-
porated by cells in the absence of TGF-b.
See also Figure S6.To ascertain whether any causal relationship between
PHRF1 loss and tumor pathogenesis could exist, we first car-
ried out a set of experiments to establish whether restoring
expression of PHRF1 in the PHRF1-defective cancer cell line
MCF7-TR could rescue TGF-b cytostatic signaling. We found
these cells to be impaired in their capacity to support the as-
sembly of the cPML/SARA complex, a defect that was cor-
rected by restoration of PHRF1 expression (Figure 6E). The
ability of PHRF1 to rescue the assembly of the cPML/SARA
complex is physiologically relevant because expression of
PHRF1 also rendered these cells sensitive to TGF-b-induced
phosphorylation of Smad2, expression of PAI-1, and growth
arrest (Figures 6F and 6G). It should be noted that restoration
of PHRF1 expression in BT20 cells failed to restore TGF-b
signaling, suggesting that these cells might accumulate alter-
ations in other components of this pathway (data not shown).
Regardless of the mechanism behind the loss of TGF-b
signaling in BT20, the data outlined so far suggest that the
PHRF1 level may exert profound influence on TGF-b signaling
in breast cancer cells. However, this concept is not limited to
breast cancer cells because we have found by serendipity538 Cell Reports 4, 530–541, August 15, 2013 ª2013 The Authorsthat the melanoma cell line MDA-
MB435 (used in this study because it
was initially thought to be a breast can-
cer cell line) is deficient in PHRF1
expression (Figures 6C and 6D). Hereagain, restoration of PHRF1 expression in MDA-MB435 was
able to rescue TGF-b responses (Figures S6D–S6G).
Dysfunction of the TGF-b cytostatic program is a prominent
hallmark of human cancers (Derynck et al., 2001; Dumont and
Arteaga, 2003; Massague´, 2008). Because PHRF1 appears to
exert a tight control over this aspect of TGF-b signaling, we
were curious if PHRF1 deficiency could provide a selective
growth advantage to breast tumor cells. We chose to
tackle this question by determining whether restoring expression
of PHRF1 in MCF7-TR cells could affect their propensity to form
tumors. Analysis of tumor growth in mice revealed that restora-
tion of PHRF1 expression did indeed suppress tumor growth
(Figures 7A–7C and S7A–S7C). This effect could be attributable
to restoration of autocrine TGF-b cytostatic signaling because
MCF7-TR cells were found to secrete TGF-b, and more crucially,
depletion of TbRII blocked the ability of PHRF1 to suppress tu-
mor formation in vivo (Figures 7A–7C). Similar results were ob-
tained when tumor growth was analyzed using an in vitro surro-
gate assay for tumorigenicity: the soft agar colony-forming assay
(Figure 7D). We also investigated whether PHRF1 restricts tumor
formation by a mechanism dependent on TGIF degradation. The
B C 
D 
A 
E 
Figure 7. PHRF1 Suppresses Tumor
Formation
(A) Expression of PHRF1, TbRII, and TGF-b1
(secreted into media) in MCF7-TR cells stably
transfected with the indicated combinations of
scrambled, PHRF1, and sh-TbRII.
(B and C) Examination of the ability of the different
cell lines generated in (A) to form tumors in athymic
nude mice. (B) Representative photographs of
tumors were taken at day 20 after inoculation.
(C) Tumor volumes were measured, and the re-
sults were expressed as mean ± SD of measure-
ments obtained with six animals in each group.
(D) The anchorage-independent growth of the
different cell lines generated in (A) was determined
using soft agar prepared with media containing
phenol red. Color photographs of live colonies
were taken by a phase-contrast microscope.
(E) A model depicting the link of PHRF1 to the
TGIF/PML-RARa/cPML signaling axis is shown.
See also Figure S7.result revealed that expression of PHRF1 was ineffective in sup-
pressing the growth of MCF7-TR cells coexpressing the degra-
dation-resistant mutant, TGIF.K130R (Figures S7A–S7C). More-
over, expression of the catalytic-inactive mutant PHRF1.CA was
unable to suppress the growth of MCF7-TR cells in mice and soft
agar (Figures S7A–S7C). During the course of these analyses, we
also found that restoration of PHRF1 expression in MDA-MB435
cells suppressed tumor formation, whereas PHRF1.CAwas inef-
fective (Figures S7D–S7G). Together, these findings strongly
suggest that PHRF1 may exert a tumor-suppressive function.
DISCUSSION
In the present work, we report on the identification of PHRF1 as a
ubiquitin ligase that targets TGIF for degradation. We propose a
model in which PHRF1 contributes to Smad signaling by desta-
bilizing TGIF and thereby facilitating the relocalization of cPML
into the cytoplasm, where it coordinates phosphorylation of
Smad2 by the activated TbRI (Figure 7E). Based on the location
of the PHRF1 gene within the tumor suppressor locus 11p15.5,
we went on to show that human breast cancer biopsies and
breast cancer cell lines display frequent loss of PHRF1 and
that restoration of PHRF1 activity in PHRF1-deficient cancer
cells is sufficient to hamper their mitogenic behavior. Thus, our
findings on the mode of action of PHRF1 provide critical insights
into the role of a key component of the TGF-b tumor suppressor
network in malignant transformation.
Although TGIF is well established as a critical negative regu-
lator of the TGF-b cytostatic program in many cell systems,Cell Reports 4, 530–541our knowledge of the regulation of its
expression or posttranslational modifica-
tion remains limited. The findings outlined
in the present study provide molecular
evidence that PHRF1 functions as a ubiq-
uitin ligase to promote TGIF degradation
through the proteasome pathway. We
identified Lys130 as the major residuethat is targeted by PHRF1 and showed that its mutation led to
increased TGIF stability. Thus, by eliciting a highly stringent con-
trol over the availability of TGIF, PHRF1 fulfills its function in an
important regulatory position in the TGF-b signaling pathway.
This would provide a mechanism to enable cells to reach a suit-
able level of TGF-b stimulation that ensures proper maintenance
of cell fate and tissue homeostasis. Because PHRF1 dissociates
from TGIF upon prolonged activation of TGF-b signaling, another
alternative possibility is that PHRF1 functions to restrict a nega-
tive feedback loop, thereby maintaining low abundance of the
TGIF protein, which would allow cells to respond efficiently to
a new acute activation of TGF-b signaling.
Of particular interest, our findings place cPML downstream of
PHRF1 in the TGF-b signaling pathway, enlightening the require-
ment of intact PHRF1 function in activation of cPML. Inactivation
of cPML appeared to play a crucial role in the pathogenesis of
many types of human cancers, although the basis of its inactiva-
tion remains to be fully elucidated. Therefore, our demonstration
that PHRF1 and cPML functions are interconnected in a tightly
regulated signaling circuit that integrates TGF-b cytostatic sig-
nals, together with the fact that cPML function is impaired in cells
deficient in PHRF1, opens avenues for improving our under-
standing of the role of the tumor suppressor cPML in neoplastic
transformation.
The mapping of the PHRF1 gene to the tumor suppressor
locus 11p15.5 motivated our attempts to search for possible
alterations of PHRF1 function in human cancers. Our attention
turned particularly to breast cancer, which displays a high fre-
quency of LOH at this locus (Ali et al., 1987; Karnik et al., 1998;, August 15, 2013 ª2013 The Authors 539
Winqvist et al., 1995). It is now well established that breast can-
cers progress through accumulation of genomic and epigenomic
aberrations that often disable the cytostatic function of TGF-b,
endowing malignant cells with the capability to proliferate and
metastasize when exposed to TGF-b (Dumont and Arteaga,
2003; Massague´, 2008). The molecular basis for the loss of
TGF-b cytostatic responses has been elusive in most instances.
Because TGF-b receptors or downstream Smad signal trans-
ducers are rarely inactivated in human breast cancer (Derynck
et al., 2001; Dumont and Arteaga, 2003), it is conceivable that
alterations in the expression or activity of uncharacterized com-
ponents that operate downstream of the core TGF-b signaling
pathway disable TGF-b’s tumor-suppressive activities. Our
study suggests that PHRF1 could represent a potential candi-
date for such a component because the loss of PHRF1 in breast
cancer cells is associated with the loss of TGF-b signaling, and
restoration of its expression not only rescued TGF-b responsive-
ness but also blocked their capability to form tumors. Thus, we
anticipate that unveiling PHRF1 as an essential component of
the TGF-b cytostatic program, and validating the link of PHRF1
to the cPML tumor suppressor network in the mammary tissue,
will hold tantalizing insights for meaningful progress in under-
standing the complex etiology of this overwhelming disease.
Allelic loss at 11p15.5 occurs in a high proportion of breast
cancer (up to 65%) and other solid tumors, suggesting the pres-
ence of tumor suppressor gene(s) within this region (Ali et al.,
1987; Jonas and Kimonis, 2001; Karnik et al., 1998; Winqvist
et al., 1995). However, positional cloning efforts to identify the
tumor suppressor genes(s) have been complicated by the high
frequency and complexity of LOH at 11p15.5 (Karnik et al.,
1998). Thus, by showing hat PHRF1 is deleted or silenced in a
high proportion of breast cancers, our study provides compel-
ling evidence that PHRF1 could represent a strong candidate
for a tumor suppressor gene at 11p15.5. This finding together
with the recent demonstration that PHRF1 is frequently deleted
across a large number of tumors (4,404 tumors) or somatically
mutated in breast cancer and other types of malignancies
strongly suggests that PHRF1 might fulfill a tumor suppressor
function. Whether PHRF1 also functions as a tumor promoter
at late stages of carcinogenesis, where TGF-b paradoxically
acts as a potent prometastatic factor, remains to be established
(Derynck et al., 2001). Besides alterations of PHRF1 in cancers,
the PHRF1 gene was also found to be frequently mutated in
systemic lupus erythematosus (SLE), an autoimmune disease
that sometimes develops alongside breast cancer in patients
(Harley et al., 2008; Kontos and Fentiman, 2008). Given the
connection of PHRF1 to the pathogenesis of breast cancers,
it will be relevant to investigate the clinical importance of
these somatic alterations in large cohorts of patients displaying
both SLE and breast cancer, which could reveal whether
PHRF1 deficiency represents a common basis for SLE and
breast cancers.
In conclusion, our identification of PHRF1 as a potential tumor
suppressor gene constitutes an appreciable advance in unravel-
ing mechanistic paradigms of breast cancer and other malig-
nancies, allowing the perception of the PHRF1/TGIF/cPML
signaling module as an important target for developing novel
therapies for these diseases.540 Cell Reports 4, 530–541, August 15, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
Cell Culture
All cell lines were cultured in DMEM supplemented with 10% fetal calf serum
(FCS). For all experiments involving TGF-b, cells were cultured inmedium con-
taining 0.5% FCS for 24 hr before being treated with 200 pM TGF-b1 (Sigma-
Aldrich), unless the concentrations are specified in the figures.
Immunoprecipitation and Immunoblotting
Cell lysates were prepared using TNMG buffer as previously described by
Demange et al. (2009). Cells extracts were cleared by centrifugation and
incubated with the appropriate antibody for 2 hr, followed by adsorption to
Sepharose-coupled protein G for 1 hr. Immune complexes were washed
five times with TNMG buffer, separated by SDS-PAGE, and analyzed by
immunoblotting.
Immunofluorescence Analysis
Cells were fixed in 4%paraformaldehyde for 30min and permeabilized in 0.1%
Triton X-100. Cells were then incubated with anti-PML or anti-TGIF antibodies
for 2 hr at room temperature and washed three times with PBS before being
incubated with the secondary antibody conjugated to Texas red or FITC for
1 hr at room temperature. After washing three times with PBS, the nuclei
were stained with DAPI, washed three times with PBS, and the coverslips
were mounted in PBS containing 50% glycerol and viewed on a fluorescence
microscope.
Real-Time PCR
Poly(A)+ RNA was prepared using the RNeasy Mini Kit (QIAGEN). cDNA was
synthesized using 1 mg of total RNA and SuperScript 2 according to the
manufacturer’s instructions (Invitrogen). A total of 50 ng of cDNA was mixed
with 12.5 ml iQ SYBR Green Supermix (Bio-Rad), 10.5 ml of water, and 0.5 ml
of 10 mMsense and antisense primers, denatured at 95C for 3min, and ampli-
fied by 40 cycles of 95C/57C/72C for 30 s each using an iCycler (Bio-Rad).
All samples were normalized to GAPDH expression.
Analysis of DNA Synthesis by BrdU
The evaluation of cell proliferation by the incorporation of bromodeoxyuridine
(BrdU) was performed using a BrdU cell proliferation assay kit following
the manufacturer’s instructions (Cell Signaling Technology). Briefly, cells
were plated, and 24 hr later, they were treated with or without TGF-b for
24 hr before being incubated with BrdU for the last 16 hr at 37C. After
removing BrdU, the cells were incubated with the fixing/denaturing solu-
tion for 30 min at room temperature and then with peroxidase-conjugated
anti-BrdU antibodies at room temperature for 30 min. The substrate for
peroxidase was added at room temperature for 30 min, and the reaction
was terminated by the addition of the stop solution. The absorbance of
each sample at 450 nm was measured by a standard spectrophotometer-
based procedure.
Tumor Growth Assays
Base layers consisting of growth medium (with phenol red) containing 0.5%
agarose were poured onto p60 dishes and allowed to solidify. A total of
5,000 cells were plated in top layers consisting of growth medium containing
0.25% agarose, and colonies were visualized after 2–3 weeks.
For xenograft studies, 2 3 106 cells were inoculated subcutaneously into
4-week-old athymic mice. Tumor formation was monitored visually, and
volumes of tumors were measured every 5 days. The INSERM Animal Care
approved all of the animal studies. See the Extended Experimental Procedures
for more information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.07.009.
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